JPWO2022173033A1 - - Google Patents

Info

Publication number
JPWO2022173033A1
JPWO2022173033A1 JP2022580703A JP2022580703A JPWO2022173033A1 JP WO2022173033 A1 JPWO2022173033 A1 JP WO2022173033A1 JP 2022580703 A JP2022580703 A JP 2022580703A JP 2022580703 A JP2022580703 A JP 2022580703A JP WO2022173033 A1 JPWO2022173033 A1 JP WO2022173033A1
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022580703A
Other languages
Japanese (ja)
Other versions
JPWO2022173033A5 (cg-RX-API-DMAC7.html
JP7725511B2 (ja
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of JPWO2022173033A1 publication Critical patent/JPWO2022173033A1/ja
Publication of JPWO2022173033A5 publication Critical patent/JPWO2022173033A5/ja
Application granted granted Critical
Publication of JP7725511B2 publication Critical patent/JP7725511B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2022580703A 2021-02-15 2022-02-14 4-アミノキナゾリン化合物 Active JP7725511B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2021021684 2021-02-15
JP2021021684 2021-02-15
PCT/JP2022/005583 WO2022173033A1 (ja) 2021-02-15 2022-02-14 4-アミノキナゾリン化合物

Publications (3)

Publication Number Publication Date
JPWO2022173033A1 true JPWO2022173033A1 (cg-RX-API-DMAC7.html) 2022-08-18
JPWO2022173033A5 JPWO2022173033A5 (cg-RX-API-DMAC7.html) 2024-02-08
JP7725511B2 JP7725511B2 (ja) 2025-08-19

Family

ID=82838845

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022580703A Active JP7725511B2 (ja) 2021-02-15 2022-02-14 4-アミノキナゾリン化合物

Country Status (12)

Country Link
US (1) US20240150366A1 (cg-RX-API-DMAC7.html)
EP (1) EP4293025B1 (cg-RX-API-DMAC7.html)
JP (1) JP7725511B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230145360A (cg-RX-API-DMAC7.html)
CN (1) CN116867788B (cg-RX-API-DMAC7.html)
AU (1) AU2022219651A1 (cg-RX-API-DMAC7.html)
CA (1) CA3211110A1 (cg-RX-API-DMAC7.html)
ES (1) ES3054794T3 (cg-RX-API-DMAC7.html)
MX (1) MX2023009520A (cg-RX-API-DMAC7.html)
PL (1) PL4293025T3 (cg-RX-API-DMAC7.html)
SA (1) SA523450286B1 (cg-RX-API-DMAC7.html)
WO (1) WO2022173033A1 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7629580B1 (ja) 2022-01-21 2025-02-13 ユーシノヴァ・ファーマシューティカルズ・リミテッド ベンゾピリミジン化合物及びその使用
CA3255513A1 (en) * 2022-03-11 2025-03-04 Astellas Pharma Inc. HETEROCYCLIC COMPOUND TO INDUCE DETERIORATION OF G12D MUTATION KRAS PROTEIN
EP4568674A1 (en) * 2022-08-12 2025-06-18 Astellas Pharma Inc. Combination of anticancer agents comprising a bifunctional compound with g12d mutant kras inhibitory activity
AU2023322690A1 (en) * 2022-08-12 2025-03-20 Astellas Pharma Inc. Anti cancer combinations comprising chemotherapy
WO2024188281A1 (zh) * 2023-03-13 2024-09-19 南京明德新药研发有限公司 含喹唑啉结构的化合物及其应用
WO2025052649A1 (ja) * 2023-09-08 2025-03-13 アステラス製薬株式会社 単一の軸不斉化合物の選択的製造法
US20250109147A1 (en) 2023-09-08 2025-04-03 Gilead Sciences, Inc. Kras g12d modulating compounds
US20250114346A1 (en) 2023-10-09 2025-04-10 Incyte Corporation Combination therapy using a kras g12d inhibitor and pd-1 inhibitor or pd-l1 inhibitor
KR20260110993A (ko) 2023-10-09 2026-07-14 인사이트 코포레이션 Kras g12d 억제제 및 egfr 억제제를 포함하는 암 치료용 조합
US20260137674A1 (en) 2024-10-23 2026-05-21 Incyte Corporation Combination therapy using a kras g12d inhibitor, and a nucleoside analog, and/or a microtubule inhibitor
WO2026090333A1 (en) 2024-10-23 2026-04-30 Incyte Corporation Combination using a kras g12d inhibitor and chemotherapy combinations as well as their use in the treatment of cancer

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017172979A1 (en) * 2016-03-30 2017-10-05 Araxes Pharma Llc Substituted quinazoline compounds and methods of use
WO2018143315A1 (ja) * 2017-02-02 2018-08-09 アステラス製薬株式会社 キナゾリン化合物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10011600B2 (en) 2014-09-25 2018-07-03 Araxes Pharma Llc Methods and compositions for inhibition of Ras
WO2016049565A1 (en) 2014-09-25 2016-03-31 Araxes Pharma Llc Compositions and methods for inhibition of ras
CN114222743A (zh) * 2019-08-16 2022-03-22 劲方医药科技(上海)有限公司 氧代六元环并嘧啶类化合物,其制法与医药上的用途
CN114615981B (zh) 2019-08-29 2024-04-12 米拉蒂治疗股份有限公司 Kras g12d抑制剂
WO2021106231A1 (en) * 2019-11-29 2021-06-03 Taiho Pharmaceutical Co., Ltd. A compound having inhibitory activity against kras g12d mutation

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017172979A1 (en) * 2016-03-30 2017-10-05 Araxes Pharma Llc Substituted quinazoline compounds and methods of use
WO2018143315A1 (ja) * 2017-02-02 2018-08-09 アステラス製薬株式会社 キナゾリン化合物

Also Published As

Publication number Publication date
EP4293025B1 (en) 2025-10-29
WO2022173033A1 (ja) 2022-08-18
PL4293025T3 (pl) 2026-02-16
SA523450286B1 (ar) 2024-06-12
EP4293025A1 (en) 2023-12-20
CA3211110A1 (en) 2022-08-18
JP7725511B2 (ja) 2025-08-19
KR20230145360A (ko) 2023-10-17
MX2023009520A (es) 2023-08-24
EP4293025A4 (en) 2025-02-26
US20240150366A1 (en) 2024-05-09
ES3054794T3 (en) 2026-02-06
EP4293025C0 (en) 2025-10-29
CN116867788B (zh) 2026-05-26
CN116867788A (zh) 2023-10-10
AU2022219651A1 (en) 2023-09-07

Similar Documents

Publication Publication Date Title
BR102021007058A2 (cg-RX-API-DMAC7.html)
BR102020022030A2 (cg-RX-API-DMAC7.html)
BR102021013306B1 (pt) Disposição introduzida em forno de pizza, com dispostivo de regulagem de altura da esteira com ajustes gradual escalonado
BR102021010942B1 (pt) Dispositivo mecânico para abertura e fechamento de portas para diferentes tipos de maçaneta, bola ou alavanca, acionado por pedal
BR102021010384B1 (pt) Equipamento para limpeza e/ou teste de bicos injetores com alta pressão
BR102021009961B1 (pt) Sistema e método para aproveitamento da água de injeção dessulfatada de plataformas marítimas para utilização em squeezes de inibição
BR102021007825B1 (pt) Equipamento de entretenimento e contemplação visual por cabines rotacionais e com giro radial e axial de 360 graus, para instalação em coberturas de edificações, penhascos ou encostas de elevações geográficas abissais
BR102021006565B1 (pt) Máquina de acabamento de estradas e método para operar a mesma
BR102021005700B1 (pt) Selo irregular para redução de ruído em aeronaves
BR102021005383B1 (pt) Método de perfurar um furo de poço marítimo com circulação reversa de fluido sem uso de tubulares de riser de perfuração
BR102021004908B1 (pt) Equipamento gerador de dióxido de cloro com processamento em alta pressão em reator com três zonas de operação para tratamento de águas e efluentes
BR102021003589B1 (pt) Método para fabricar uma estrutura monolítica em formato de caixa para fuselagens e asas de aeronave usando um material prepreg de matriz de polímero reforçada com fibra
BR102021003353B1 (pt) Aerofólio compósito estrutural, aeronave e método de montagem de um aerofólio compósito estrutural
BR102021000474B1 (pt) Aparelho de pino de medição, sistema de amortecimento multiator, e, conjunto de amortecedor de impacto
BR102020026775B1 (pt) Montagem de painel de malha de arame soldado e uma ou mais armações, e parede ou teto reforçado por uma ou mais montagens
BR102020026302B1 (pt) Processo de produção de corante natural azul
BR102020023974B1 (pt) Revestimento de amarras para redução de arrasto longitudinal
BR102020021170B1 (pt) Composição, formulações orais e uso
BR102020018864B1 (pt) Grade de ventilação modular
BR102020018483B1 (pt) Dispositivo mecânico para arraste de cabeçote móvel para realização de furos, alargamentos, roscas com machos por intermédio de automatização em tornos mecânicos horizontais
BR102020016764B1 (pt) Forma de dosagem intrauretral de medicamento; e dispositivo
BR102020013192B1 (pt) Distribuidor de fertilizante sólido para equipamentos agrícolas, e equipamento agrícola dotado de distribuidor de fertilizante sólido
BR102020007524B1 (pt) Sistema de montagem e controle de acumuladores em estações de trabalho
BR102020005641B1 (pt) Método integrado de cultura do peixe lambari-do-rabo-amarelo, camarão-da-amazônia e o peixe curimbatá
BR102020004560B1 (pt) Rotor eólico utilizando duplas-pás inteiriças para geração de potência

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230612

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240131

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240809

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250522

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250527

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250729

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250806

R150 Certificate of patent or registration of utility model

Ref document number: 7725511

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150